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Introduction
The immunosuppressant mycophenolic acid (MPA) is metabolised primarily by glucuronidation in the liver (Bowalgaha and Miners, 2001 ) to form the inactive metabolite mycophenolate ether glucuronide (MPAGe) and the active metabolite mycophenolate acyl glucuronide (MPAGa) (Shipkova et al., 1999) . In humans, the uridine diphosphate glucuronosyl transferases (UGT's) responsible for the formation of MPAGe and MPAGa are UGT1A9 (Bowalgaha and Miners, 2001 ) and UGT2B7 (Picard et al., 2005) , respectively. Picard et al (2005) identified a minor metabolite, 6-Odesmethyl-MPA (DM-MPA) as a product of cytochrome P450 (CYP) 3A4/5 and CYP2C8 (Picard et al., 2005) . MPAGe undergoes extensive biliary secretion and in the gut is hydrolysed by bacterial β-glucuronidase to reform MPA, which undergoes enterohepatic recirculation (Bullingham et al., 1996b) . It has been estimated that between 10-61% of the MPA area under the plasma concentration versus time curve (AUC) may be due to enterohepatic recirculation which results in a second peak in the concentration time profile of MPA at approximately 8-12 hr following the administration of mycophenolate mofetil (the prodrug of MPA) (Bullingham et al., 1996a) .
A drug interaction has been described in patients co-administered the immunosuppressants cyclosporine (CsA) and MPA that results in a decrease in plasma MPA concentrations (Smak Gregoor et al., 1999; Filler et al., 2001; Brown et al., 2002; Kuypers et al., 2003) . Most pharmacokinetic interactions involving calcineurin inhibitors, such as CsA, involve substrates for intestinal and hepatic P-glycoprotein and the CYP3A enzyme family (Bohme et al., 1993; Lin and Lu, 1998) . However, CsA has been shown to inhibit the UGT-catalysed metabolism of MPA (Zucker et al., 1999) (Shitara et al., 2002; Shitara et al., 2003) .
Similar to humans, the metabolism of MPA in isolated perfused Wistar rat livers results primarily in the formation of MPAGe (84% of added MPA) and a much smaller fraction of MPAGa (3.9%). Using TR-rats, a strain of mutant Wistar rats lacking the Mrp2 transporter (Soroka et al., 2001) , Mrp2 has been shown to be the key transporter involved in MPAGe biliary excretion in rats (Kobayashi et al., 2004; Hesselink et al., 2005; Westley et al., 2006) . We have previously reported that in perfused TR -rat livers, the clearance (CL) and hepatic extraction ratio (E H ) of MPA were significantly lower compared to control Wistar rats (Westley et al., 2006 (Westley et al., 2006) .
A previous study has reported altered phase-I metabolic activity in TR -rats compared to
Wistar rats (Jager et al., 1998 
Microsomal Preparation
Microsomes from rat livers were prepared by differential centrifugation as described by Zanger et al, (1988) , resuspended in sucrose-tris buffer (0.25M sucrose, 0.05M Trisma) pH 7.4 and stored at -80ºC until use. 9 mg/ml) and 50 µL of BSA standards or rat liver microsome suspension were added to 2.5 mL filtered dye reagent. BSA standards and microsomal sample absorbances were read at 595 nm on a Beckman DV-70 Spectrophotometer (Fullerton, CA, USA).
Microsomal metabolism of MPA to MPAGe
Enzyme Kinetics
Microsomal protein, 1.0 mg/ml or 0.5 mg/ml for control and TR -rats respectively, was incubated at 37°C with 0.5 mg/ml alamethicin, 5 µg/ml MPAGe was measured by high performance liquid chromatography (HPLC) (Westley et al., 2005) . MPAGa formation was not determined due to insufficient compound available to prepare calibrator stocks.
Under the conditions described above MPAGe reaction rates were found to be linear with respect to incubation time and microsomal protein concentration. All incubations were This article has not been copyedited and formatted. The final version may differ from this version. 
Inhibition Studies
The formation of MPAGe from MPA (50µM) was also investigated using control Wistar liver microsomes (1 mg/ml protein) in the absence or presence of potential inhibitors of glucuronidation, CsA (20 mM), metabolites AM1 (100 µM), AM1c (100 µM), AM9 (100 µM) or MPAGa (200µM). CsA and its metabolites were investigated because CsA is often co-administered with MPA and has been shown to alter the clinical pharmacokinetics of MPA. AM1 and AM9 were chosen as they are the major primary metabolites of CsA, whilst AM1c was chosen as it is a substrate for glucuronidation (Christians and Sewing, 1995) . Incubation and activation conditions were as described above. We previously determined that there was no significant hydrolysis of MPAGa to MPA during the incubation (data not shown).
Hydrolysis of MPAGe
The hydrolysis of MPAGe by microsomal β-glucuronidase was investigated by measuring MPA formation during incubation of MPAGe (200 µM) at 37ºC in the presence of 1 mg microsomal protein from control Wistar and TR -rats. The incubation was terminated at 10 min by sampling 100 µL of the reaction mixture. On addition of acetonitrile containing internal standard, samples were placed on ice and MPA concentrations were determined by HPLC (Westley et al., 2005) . Control samples 
HPLC analysis
The concentrations of MPAGe or MPA were determined by HPLC analysis as previously described by Westley et al, (2005) . Briefly, 100 µL of each sample were added to 250 µL of acetonitrile containing the internal standard, carboxy butoxy ether mycophenolic acid 
Kinetic analyses
Kinetic parameters for the formation of MPAGe were determined using the Michaelis 
RESULTS
Kinetic analysis of MPAGe Formation
Mean (S.E.M.) liver weights in control Wistar and TR -rats were 13.4 (0.6) g and 17.1 (0.6) g, respectively. Protein concentrations were 19.8 (2.0) mg/ml and 24.8 (0.8) mg/ml, respectively. The mean liver weights of the TR -rats were significantly greater than those of the Wistar rats, but there was no difference in microsomal protein concentrations. The significant difference in rat and liver weights identified in this study is consistent with those differences seen by Jager et al, (2003) . 
Mean (S.E.M.) V max values for the control and TR
Hydrolysis of MPAGe
The degradation of MPAGe to MPA by β-glucuronidase was investigated during 10 min This article has not been copyedited and formatted. The final version may differ from this version. and 1A7 expression may not be up regulated in TR -rats.
For example, similar observations have been reported for phase-I metabolism. Jager et al (1998) demonstrated that differences in the total CYP450 content may be due to differential expression of individual isoenzymes in various mutant rat strains. Newton et al (2005) showed that CYP2B1/2 mediated pentoxyresorufin О -demethylation activity as well as CYP2C11 mediated 2α-and 16α-hydroxylase activities were higher in TR -rats further demonstrating variation in mutant strains.
Another possible explanation for the lower in situ hepatic clearance of MPA in TR -rats may be decreased uptake into the hepatocytes. In addition, it is possible that MPAGe and MPAGa compete with MPA for hepatic uptake and, in the Mrp2 deficient rats, increased
MPAGe and MPAGe basolateral efflux from hepatocytes results in increased inhibition of MPA uptake into hepatocytes. This may result in the decreased CL and E H of MPA, and prolonged MPA AUC and t 1/2 previously reported in TR -rat liver perfusions (Westley et al., 2006) . Other glucuronide conjugates have been reported to compete with parent aglycones for uptake transporters. For example, Sesink et al, (2005) nmol/mg protein/min versus 6.7 nmol/mg protein/min, respectively, and mean K m of 0.08 mM versus 0.20 mM respectively. The data from this study are consistent with the species differences in the metabolic capabilities between rat liver microsomes and HLM.
Furthermore, Miles et al (2005) demonstrated the affinity and capacity of the three UGT's (UGT1A1, 1A6 and 1A7) responsible for the metabolism in Sprague-Dawley rats.
In our study, K m values were similar to those reported by Miles et al (2005) , but Vmax values were approximately 10-fold lower. This may be attributed to rat strain differences Wistar rats, CsA may inhibit the rat UGT isoforms catalysing MPAGe formation at concentrations much lower than the Ki reported by Zucker et al (1999) . Picard et al, (2005) have also reported that different human UGT's are involved in the formation of MPAGe and MPAGa. CsA is a known substrate for UGT2B7 (Strassburg et al., 2001) , the isoform catalysing the formation of MPAGa in humans.
The significant increase in MPAGe formation in the presence of AM1 suggests positive cooperativity with the UGT's involved in MPA metabolism in Wistar rats. Homotropic positive cooperativity has been observed for the human UGT2B7 nonselective substrate 4-methylumbelliferone (Miners et al., 2004) and estradiol 3-glucuronidation by the addition of UGT1A1 substrates (Williams et al., 2002) . A similar effect has also previously been demonstrated for CYP enzymes in human liver microsomes. For example, in the activation of CYP2C9-catalyzed tolbutamide hydroxylation by lansoprazole (Liu et al., 2005) , and for the stimulation of CYP3A4 mediated metabolism of warfarin by quinidine (Ngui et al., 2001) . Although, we were unable to obtain recombinant rat UGT1A1 and 1A7 to further investigate this effect and identify the UGT involved, this data is the first of its kind to suggest positive cooperativity in rat UGT's.
Further work is required to determine whether this may be clinically relevant.
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